Insider Trading Alert - EXPD, HCN And ADVS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 10, 2014, 94 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $418.41 to $20,729,358.41.

Highlighted Stocks Traded by Insiders:

Expeditors International of Washington (EXPD) - FREE Research Report

Emmert Mark A, who is Director at Expeditors International of Washington, sold 4,747 shares at $44.09 on Nov. 10, 2014. Following this transaction, the Director owned 17,435 shares meaning that the stake was reduced by 21.4% with the 4,747-share transaction.

The shares most recently traded at $44.26, up $0.17, or 0.38% since the insider transaction. Historical insider transactions for Expeditors International of Washington go as follows:

  • 4-Week # shares sold: 6,747
  • 12-Week # shares sold: 6,747
  • 24-Week # shares sold: 86,747

The average volume for Expeditors International of Washington has been 1.3 million shares per day over the past 30 days. Expeditors International of Washington has a market cap of $8.5 billion and is part of the services sector and transportation industry. Shares are up 0.11% year-to-date as of the close of trading on Monday.

Expeditors International of Washington, Inc. provides logistics services. The stock currently has a dividend yield of 1.45%. The company has a P/E ratio of 24.6. Currently, there are 5 analysts who rate Expeditors International of Washington a buy, 2 analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EXPD - FREE

TheStreet Quant Ratings rates Expeditors International of Washington as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Expeditors International of Washington Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Health Care REIT (HCN) - FREE Research Report

Brinker Scott M, who is EVP - Chief Investment Officer at Health Care REIT, sold 4,286 shares at $70.84 on Nov. 10, 2014. Following this transaction, the EVP - Chief Investment Officer owned 48,965 shares meaning that the stake was reduced by 8.05% with the 4,286-share transaction.

The shares most recently traded at $70.85, up $0.01, or 0.01% since the insider transaction. Historical insider transactions for Health Care REIT go as follows:

  • 4-Week # shares bought: 2,400
  • 4-Week # shares sold: 1,325
  • 12-Week # shares bought: 2,400
  • 12-Week # shares sold: 4,825
  • 24-Week # shares bought: 2,400
  • 24-Week # shares sold: 14,241

The average volume for Health Care REIT has been 2.4 million shares per day over the past 30 days. Health Care REIT has a market cap of $23.1 billion and is part of the financial sector and real estate industry. Shares are up 32.8% year-to-date as of the close of trading on Monday.

Health Care REIT, Inc. is an independent equity real estate investment trust. The firm engages in acquiring, planning, developing, managing, repositioning and monetizing of real estate assets. It primarily invests in the real estate markets of the United States. The stock currently has a dividend yield of 4.5%. The company has a P/E ratio of 78.5. Currently, there are 6 analysts who rate Health Care REIT a buy, 2 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HCN - FREE

TheStreet Quant Ratings rates Health Care REIT as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, compelling growth in net income, revenue growth, reasonable valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Health Care REIT Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Advent Software (ADVS) - FREE Research Report

Tarkoff Robert M, who is Director at Advent Software, sold 2,500 shares at $34.85 on Nov. 10, 2014. Following this transaction, the Director owned 2,534 shares meaning that the stake was reduced by 49.66% with the 2,500-share transaction.

The shares most recently traded at $33.43, down $1.42, or 4.26% since the insider transaction. Historical insider transactions for Advent Software go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 3,000
  • 24-Week # shares sold: 5,718

The average volume for Advent Software has been 374,200 shares per day over the past 30 days. Advent Software has a market cap of $1.7 billion and is part of the technology sector and computer software & services industry. Shares are down 5.58% year-to-date as of the close of trading on Monday.

Advent Software, Inc. provides software products and services for automating and integrating data and work flows across the investment management organization, as well as between the investment management organization and external parties worldwide. The stock currently has a dividend yield of 1.58%. The company has a P/E ratio of 37.9. Currently, there are 2 analysts who rate Advent Software a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ADVS - FREE

TheStreet Quant Ratings rates Advent Software as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth and good cash flow from operations. However, as a counter to these strengths, we find that the stock has experienced relatively poor performance when compared with the S&P 500 during the past year. Get the full Advent Software Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

General Motors Spikes on Report It's Considering Listing Shares of Cruise Unit

General Motors Spikes on Report It's Considering Listing Shares of Cruise Unit